Cary Fridrich Selected Research

Neoplasms (Cancer)

2/2024	Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.
11/2020	Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer.
1/2016	Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor.
1/2016	Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cary Fridrich Research Topics

Disease

4	Neoplasms (Cancer) 02/2024 - 01/2016
1	Breast Neoplasms (Breast Cancer) 02/2024
1	Cardiac Arrhythmias (Arrythmia) 01/2023
1	Atrial Fibrillation 01/2023

Drug/Important Bio-Agent (IBA)

2	Phosphotransferases (Kinase)IBA 02/2024 - 01/2016
1	LipidsIBA 02/2024
1	Glucose (Dextrose)FDA LinkGeneric 02/2024
1	Hormones (Hormone)IBA 02/2024
1	Insulin (Novolin)FDA Link 02/2024
1	Anti-Arrhythmia AgentsIBA 01/2023
1	Ion Channels (Ion Channel)IBA 01/2023
1	AminesIBA 11/2020
1	Non-Receptor Type 11 Protein Tyrosine PhosphataseIBA 01/2016
1	tyrosine receptor (receptor, tyrosine)IBA 01/2016
1	Immunologic Factors (Immunomodulators)IBA 01/2016
1	Oncogene Proteins (Oncogene Protein)IBA 01/2016
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2016
1	SHP099IBA 01/2016

Therapy/Procedure

1	Electric Countershock (Cardioversion) 01/2023
1	Therapeutics 01/2016